Emerging Trends in Atherosclerosis: Time to Address Atherosclerosis From a Younger Age.

Over the past two decades, research efforts into cardiovascular disease (CVD) have uncovered findings that fundamentally challenge our understanding of CVD, particularly atherosclerosis. Atherosclerosis was primarily attributed to the well-described abnormal lipid accumulation theory, involving plaque growth with subsequent plaque hemorrhage resulting in acute vessel thrombosis that may or may not rupture. This perspective has now evolved to encompass more complex pathways, wherein the accumulation of abnormal products of oxidation and inflammation is the most likely factor mediating atherosclerotic plaque growth. Furthermore, atherosclerosis was traditionally thought of as a disease in patients aged 40 and older. However, mounting evidence has demonstrated that significant atherosclerosis and CVD events are more prevalent in younger patients than previously realized and accelerating in incidence. With this alarming trend among younger individuals, our review sought to explore why this trend may be happening and what can be done about this developing problem.

The prevalence of the syndrome of inappropriate antidiuretic hormone secretion (SIADH) in brucellosis patients: Systematic review and meta-analysis.

BACKGROUND: Hyponatremia is a prevalent electrolyte abnormality amongst hospitalized patients. The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a common cause of hyponatremia. Minimal literature described an association between SIADH and brucellosis. This paper aimed to systematically review the literature to synthesize the prevalence of SIADH in brucellosis patients. METHODS: We comprehensively searched PubMed, EMBASE, and Google scholar for observational studies examining the prevalence of SIADH in brucellosis patients. There were no age, language, or date limitations. We used a prevalence meta-analysis using the random-effects model with double arcsine and back transformation. I squared (I2) was used to determine heterogeneity. The MetaXl software was used for statistical analysis. RESULTS: Three observational studies met our inclusion criteria. The reported prevalence of SIADH in the constituent studies ranged from 3 to 56%. The quantitative synthesis, encompassing 306 patients' data, revealed a pooled SIADH prevalence of 20% (95% CI 0.00-52%, I2 96%). The quality assessment revealed a moderate quality of included studies. The results were heterogeneous, as depicted by a high I2. DISCUSSION AND CONCLUSION: The results from this review revealed a relatively high prevalence of SIADH of 20% in patients with brucellosis. Thus, hyponatremia in patients with chronic fever should prompt SIADH and brucellosis workup, particularly in endemic brucellosis areas. Likewise, patients with brucellosis merit hyponatremia screening. More extensive studies are needed to ascertain the exact prevalence of hyponatremia and SIADH in this patient cohort and their impact on the diagnosis and the overall prognosis.

Association of menopausal symptom severity and osteoporotic fractures: a case-control study.

AIM: to find out the association between the severity of different menopausal symptoms with the occurrence of osteoporotic fractures. METHODS: case-control study of 159 patients who suffered from osteoporotic fractures and 169 controls. Data collected using a pre-validated questionnaire of the Arabic version of Menopause rating scale, in addition to other sociodemographics. RESULTS: all menopausal symptoms were more severe in women in the control group, the highest scores were reported for joint pain followed by hot flashes. Conclusion severe menopausal symptoms are linked to less osteoporotic fracture, more randomized trials are needed to prove this association.

Dasatinib-induced chylothorax: An unusual presentation of a common adverse event-A case report with literature review.

Tyrosine kinase inhibitors (TKIs) are the key agents for treating CML and BCR-ABL+ B-ALL. Dasatinib is a potent second-generation TKI. Here, we have discussed the case of a 51-year-old gentleman diagnosed with B-myeloid mixed-phenotype acute leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1p210, in complete hematological, cytogenetic, and molecular remission, who developed chylothorax. Though pleural effusion is a commonly observed adverse effect of dasatinib therapy, chylothorax is rare. The ability of Dasatinib to inhibit multiple families of tyrosine kinases could be considered the etiology. Discontinuation of the drug resolved the symptom, but pleural effusion recurred once Dasatinib was resumed. Chylothorax induced by Dasatinib is a differential to be kept in mind, owing to the limited number of cases being reported.